Protalix’s Pegunigalsidase Alfa Granted FDA Fast Track Status for Fabry Disease
The U.S. Food and Drug Administration (FDA) has granted fast track designation to pegunigalsidase alfa, or PRX-102, Protalix BioTherapeutics’ therapy…
Get regular updates to your inbox.